This transaction
Establishment of subsidiaryThe voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.The percentage before the change is not stated in this document.
• Provision, dissemination, promotion and education of information concerning reproductive medicine, fertility and health and medical care • Planning, operation, management and contract-based provision of academic conferences, study groups, lectures, seminars and other events related to medicine and academia, and related activities
The impact of this matter on our consolidated results for the fiscal year ending March 2027 is expected to be immaterial.
| Item | Details |
|---|---|
| Transaction name | Establishment of subsidiary |
| Name of the Subject Company | 株式会社FertiLink (provisional name) |
| Business Description of the Subject Company | • Provision, dissemination, promotion and education of information concerning reproductive medicine, fertility and health and medical care • Planning, operation, management and contract-based provision of academic conferences, study groups, lectures, seminars and other events related to medicine and academia, and related activities |
| Location of the Subject Company | Minato-ku, Tokyo |
| Capital Stock of the Subject Company | ¥3 million |
| Date of Establishment of the Subject Company | December 2026 (予定) |
| Type of Consideration | Cash (100% funded by the company; stated capital of ¥3 million) |
| Voting rights ownership percentage | After 100％ (before not disclosed) |
| Impact on Business Performance | The impact of this matter on our consolidated results for the fiscal year ending March 2027 is expected to be immaterial. |
| Date of board resolution | 13 November 2026 |
| Execution Date / Effective Date | December 2026 (予定) |
| Management structure after acquisition | The representative will be director Emi Abe (candidate). One of our employees is expected to concurrently serve as a director of the subsidiary. The new company's name is 株式会社FertiLink (provisional name), and the company states that it will make a further announcement if any changes occur. |
Items this document does not state (20)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The purpose is to strengthen the ability to disseminate information, a key policy of the medium-term management plan, and address barriers to access to medical care caused by insufficient information and understanding concerning reproductive medicine. The company also aims to broaden the base of the infertility treatment market and achieve sustainable business growth for the group.